Migraine Drug Trial will Test Effectiveness of MK0974 co-Administered with Ibuprofen or Acetaminophen

This phase II trial – to start in November 2008 – is not yet open for recruitment. Target enrollment is 628 migraine patients (with or without aura) who have had 1 to 8 severe attacks per month the 2 months prior to study. Locations are not yet listed.

Official Title: “A study to test the safety and effectiveness of MK0974 co-administered with ibuprofen or acetaminophen in patients with migraines with or without aura” – ClinicalTrials.gov ID# NCT00758836.

The study will compare treatment with:

• Merck experimental drug telcagepant (MK0974) only;

• MK0974 plus ibuprofen,

• MK0974 plus acetaminophen,

• And placebo.

This study follows a large phase III effectiveness & safey study of MK0907 (see the ClinicalTrialsToday.com report on that study’s findings – “Migraine Study Shows Merck’s Telcagepant Promising”).

For more information about the new study, inclusion and exclusion criteria, and a toll free contact number for questions, see the ClinicalTrials.gov listing for trial # NCT00758836

1 Star2 Stars3 Stars4 Stars5 Stars (1 votes, average: 4.00 out of 5)

Leave a Reply